Fortitude Biomedicines is developing antibody drug conjugates that use targeted protein degraders as their therapeutic payloads. The startup joins a group of degrader ADC (or DAC) developers that includes Bristol Myers Squibb and Pfizer.
The post Startup Fortitude Bio Launches to Beat Drug Resistance in Cancer, Expand ADCs to Autoimmune Disease appeared first on MedCity News.
